LICENSE AGREEMENT by and between Puma Biotechnology, Inc. and Knight Therapeutics Inc. DATE: January 9, 2019License Agreement • March 1st, 2019 • Puma Biotechnology, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “License Agreement”), effective January 9, 2019, by and between PUMA BIOTECHNOLOGY, INC., a corporation formed under the laws of Delaware (“Licensor”) and KNIGHT THERAPEUTICS INC., a corporation incorporated under the laws of Canada (“Knight”).
puma biotechnology, inc.Notice and Stock Option Agreement • March 1st, 2019 • Puma Biotechnology, Inc. • Pharmaceutical preparations • Delaware
Puma Biotechnology, Inc., a Delaware corporation (the “Company”), pursuant to its 2017 Employment Inducement Incentive Award Plan (the “Plan”), hereby grants to the individual listed below (the “Optionee”), an option to purchase the number of shares of the common stock of the Company (“Shares”), set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein and in the Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.
